Yong-Soo Bae | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Yong-Soo Bae | Immunology Cellular Interactions | Best Researcher Award

Prof. Dr. Yong-Soo Bae | Sungkyunkwan University | South Korea

Dr. Yong-Soo Bae is a distinguished immunologist and professor at the Department of Biological Science, Sungkyunkwan University, Korea. He currently serves as the Director of the SRC Center for Immune Research on Non-lymphoid Organs (CIRNOS). With over three decades of academic, clinical, and industry experience, Dr. Bae is internationally recognized for his pioneering research in immunology, virology, and vaccine development. His multidisciplinary contributions span academia, biotech innovation (as CEO/CTO of JW Creagene Inc.), and scientific leadership, including organizing global conferences and serving as editor-in-chief and president in numerous societies. His work focuses on immune modulation, cancer immunotherapy, and mucosal vaccines, which has led to influential publications in prestigious journals like Nature Communications, Science Advances, and Advanced Materials. Dr. Bae’s career reflects a commitment to innovation, collaboration, and education, making him a strong candidate for the Best Researcher Award.

Publication Profile:

Scopus

✅ Strengths for the Award

  1. Pioneering Research Leadership
    Dr. Bae has led groundbreaking research in immunology, particularly in immune regulation of non-lymphoid organs, vaccine development, and cancer immunotherapy. His leadership of the Center for Immune Research on Non-lymphoid Organs (CIRNOS) demonstrates his national influence in immune research.

  2. Extensive Scientific Contributions
    With over 18 high-impact publications in the past 3–4 years alone, including in top-tier journals like Nature Communications, Molecular Therapy, Science Advances, and Advanced Materials, Dr. Bae continues to push the boundaries of translational immunology and personalized medicine.

  3. International & Interdisciplinary Experience
    His training at Harvard Medical School, his professorships across Korean institutions, and leadership at JW Creagene Inc. showcase both academic and industrial impact.

  4. Scientific Community Engagement
    Roles such as Editor-in-Chief, society president, and organizer of global conferences (e.g., DC2012) reflect his commitment to advancing scientific dialogue and collaboration.

  5. Mentorship and Institutional Development
    Dr. Bae has contributed significantly to capacity building in Korea’s biomedical research landscape, mentoring junior scientists and shaping departmental growth.

⚠️ Areas for Improvement:

  1. Global Collaboration Visibility
    While his work is highly impactful in Korea and Asia, more joint publications with global institutions (e.g., NIH, Oxford, Karolinska) could further enhance international research influence.

  2. Patent and Commercial Output Reporting
    As former CEO/CTO of JW Creagene, elaborating on patented innovations or therapeutic products brought to market would strengthen the case for translational impact.

  3. Formal Recognition or Awards
    Inclusion of formal honors (e.g., national science medals, international society awards) would help quantify his recognition outside Korea.

  4. Consistent Author Disambiguation
    In some publications, author names appear as “Y.S. Bae” or “Yong-soo Bae.” Consistent use of a standardized author name across indexing platforms would help centralize his citation metrics and scholarly footprint.

 

🎓 Education:

Dr. Yong-Soo Bae’s academic journey began with a Bachelor’s and Master’s degree in Microbiology from Seoul National University in 1981 and 1983, respectively. His foundational training in microbiology laid the groundwork for his research trajectory in infectious disease and immunology. He earned his Ph.D. in 1990 from the University of Calgary, Alberta, Canada, in the Virology Division of the Department of Microbiology and Infectious Diseases, Faculty of Medicine. His doctoral research was crucial in shaping his interest in host-pathogen interactions and immune regulation. Dr. Bae’s international education experience has enabled him to blend Western and Eastern biomedical research paradigms, contributing to his ability to lead collaborative global projects and initiatives in immunotherapy and vaccine innovation.

💼 Experience:

Dr. Yong-Soo Bae’s professional career spans academia, research, and biotech leadership. He completed a postdoctoral fellowship at Dana-Farber Cancer Institute, Harvard Medical School (1991–1993), which enriched his expertise in cancer immunology. He held professorial roles at Hannam University (1993–2003) before joining Sungkyunkwan University in 2004, where he later became Department Chair and Distinguished Professor. Dr. Bae also served as Director of CIRNOS (2017–2024) and led JW Creagene Inc. as CEO/CTO (1998–2015), bridging science and industry. His editorial and leadership roles include Editor-in-Chief of the Journal of Bacteriology and Virology, President of the Korean Society of Virology, and Vice President of the Korean Vaccine Society. His diverse roles demonstrate a unique blend of academic excellence, organizational leadership, and translational research expertise.

🔍 Research Focus:

Dr. Yong-Soo Bae’s research focuses on innate and adaptive immune regulation, tumor immunology, mucosal immunotherapy, and vaccine delivery. He investigates cellular interactions in the immune microenvironment, with particular attention to innate lymphoid cells (ILCs), neutrophils, and dendritic cells. His translational work includes novel vaccine platforms, epitranscriptomics, immune checkpoint modulation (e.g., CISH, PD-1), and cell therapy for diseases such as asthma, leukemia, and cancer. He also explores microbiome-immune crosstalk and inflammation-related organ damage (e.g., renal fibrosis, lung inflammation). His group has published extensively on m6A modifiers, microRNAs, and innovative delivery systems like gel-to-nanovaccines. His latest studies dive into immunometabolism and the interplay between immune cells and tissue repair, offering groundbreaking insights for future immunotherapies. Dr. Bae’s work is highly cited and remains at the forefront of immune system-based therapeutic innovation.

📚 Publications Top Notes:

  1. 📘 Therapeutic Potential of microRNA Against Th2-associated Immune Disorders – Current Topics in Medicinal Chemistry (2021)

  2. 💉 COVID-19 Vaccines and Oral-Mucosal Vector System as a Potential Vaccine Platform – Vaccines (2021)

  3. 🧬 Immunotherapeutic Potential of m6A-Modifiers and microRNAs in AML – Biomedicines (2021)

  4. 🎯 Epitranscriptomic Approach to Improve ICB Therapy by Targeting CISH – Cells (2021)

  5. 🧫 TFH-B-TRM Dysregulation and Anti-PD-1 Responses in EGFR-mutant Lung Cancer – Nature Communications (2021)

  6. 🧪 Adenoviral CD200R-Ig Enhances Antitumor Immunity via M2 Macrophage Inhibition – Molecular Therapy

  7. 🌫 Air Pollutant-induced Neutrophils Worsen Airway Inflammation – JACI (2021)

  8. 🦠 NCR+ILC3s and the Microbiome in Asthma Severity – Immune Network (2021)

  9. 📖 Advances in Personalized Therapy for AML by Targeting Intracellular Checkpoints – eBook Chapter (2021)

  10. 🧵 Siglec-F Neutrophils Drive Fibrosis in Renal Disease – JCI (2022)

🧾 Conclusion:

Dr. Yong-Soo Bae is an exceptional and highly deserving candidate for the Best Researcher Award. His contributions over four decades span foundational research, translational innovation, academic leadership, and scientific diplomacy. The depth of his scientific output, particularly in immunology, epigenetics, and vaccine development, is matched by his long-term commitment to mentoring, editorial work, and building research institutions in Korea.While enhancing his global recognition and expanding international collaborative outputs could further elevate his status, Dr. Bae’s consistent high-impact contributions, research leadership, and policy involvement clearly position him as a top-tier researcher in the life sciences.

Dagmar Schmid | Immunology Cellular Interactions | Women Researcher Award

Published on by Cell Biologist

Dr. Dagmar Schmid | Immunology Cellular Interactions | Women Researcher Award

Dr. Dagmar Schmid, HOCH, Health Ostschweiz, Kantonsspital St.Gallen, Klinik für Psychosomatik und Konsiliarpsychiatrie, Switzerland

PD Dr. med. Dagmar A. Schmid is a German physician and internationally recognized expert in psychosomatic medicine, consultative psychiatry, and sleep research. Born in Neuburg/Donau in 1969, she currently serves as Chief Physician and Director at the Clinic for Psychosomatics, Cantonal Hospital St. Gallen, Switzerland. With over two decades of experience across leading institutions in Germany and Switzerland, Dr. Schmid has made significant contributions to research on chronic pain, sleep disorders, stress, trauma, and Long COVID. Her integrative, evidence-based clinical approach bridges psychotherapy, neuroendocrinology, and psychosomatic care. She is also a passionate educator, holding lectureships at UZH, ETH, HSG, and USB, and is involved in curriculum development for medical training. A Fellow of the Max Planck Society, she holds a habilitation from the University of Zurich. Dr. Schmid combines research leadership, therapeutic innovation, and interdisciplinary collaboration, making her a compelling candidate for the Research for Women Researcher Award.

Publication Profile:

Scopus

✅ Strengths Supporting Suitability for the Award:

1. Outstanding Clinical-Scientific Integration

  • PD Dr. Schmid bridges psychiatry, psychosomatics, sleep medicine, and trauma, integrating clinical practice with impactful research.

  • Her work is deeply translational, evidenced by studies like CBT for narcolepsy, multimodal pain therapy, and psychotraumatology in somatic settings.

2. Highly Relevant and Timely Research Topics

  • Research on Long COVID, psychotraumatology, insomnia, and workplace mental health is at the forefront of global health challenges.

  • Interdisciplinary projects (e.g., with neurology, gynecology, immunology) reflect innovation and relevance to both women’s and public health.

3. International Recognition & Academic Output

  • Over 40 peer-reviewed publications, including in high-impact journals.

  • Multiple first-author papers, invited talks, and poster awards reflect peer validation.

  • Recipient of prestigious awards and fellowships (e.g., Max Planck Society, Heraeus Foundation).

4. Leadership and Mentorship

  • Clinic Director and Chief Physician since 2017.

  • Responsible for establishing therapy units and sleep diagnostics services.

  • Supervises dissertations, reflecting her mentorship commitment, especially valuable for empowering future women researchers.

5. Teaching & Outreach

  • Teaching roles at major Swiss institutions (ETH, UZH, HSG, USB).

  • Leadership in educational modules on psychosomatics, communication, and sleep disorders.

  • Speaker in national specialist curricula, enhancing knowledge dissemination.

6. Focus on Women’s Health

  • Specific projects on gynecological trauma, psychosomatics in oncology, and stress-related conditions affecting women’s mental and physical health.

⚠️ Areas for Potential Improvement or Future Growth:

1. International Visibility in Gender-Specific Medicine

  • While her research is highly relevant to women’s mental health, more direct engagement in gender-specific medical research networks or global women’s health collaborations would further strengthen her candidacy.

2. Research Leadership in Consortia

  • Leading international multicenter studies or EU-funded programs would enhance her influence on policy-level decisions in women’s mental health.

3. Visibility in Advocacy and Policy

  • Greater participation in public policy or healthcare advisory roles (e.g., for WHO or national bodies) on topics like Long COVID in women or trauma-informed care would expand her societal impact.

🎓 Education:

Dr. Schmid earned her medical doctorate at the Max Planck Institute of Psychiatry, Munich, with a dissertation on hormone secretion and sleep EEG in depression. From 1998 to 2002, she held a prestigious scholarship from the Max Planck Society, further advancing her research in psychoneuroendocrinology. Her habilitation (postdoctoral qualification) was completed at the University of Zurich in 2023, titled “Psychophysiology in Psychosomatics Using Sleep as an Example”. She is a certified specialist in psychiatry and psychotherapy in both Germany and Switzerland. Her therapeutic training includes Cognitive Behavioral Therapy (CBT), Dialectical Behavioral Therapy (DBT), Interpersonal Psychotherapy (IPT), EMDR trauma therapy, hypnotherapy, and CBASP for chronic depression. Dr. Schmid has also completed the GCP clinical research certification, the SIM expert certificate, and advanced training in psycho-oncology. Her interdisciplinary education forms the foundation of her clinical innovation and scientific impact.

💼 Professional Experience:

Dr. Schmid has held senior positions in top psychiatric and psychosomatic institutions. From 1998–2002, she worked at the Max Planck Institute, followed by clinical roles in Zurich and Basel. At Clienia Schlössli AG, she led psychotherapy and DBT programs, later joining the University Hospital Zurich, working in sleep medicine, liaison psychiatry, and emergency psychiatry. Since 2017, she is Chief Physician and Clinic Director for Psychosomatics and Consultant Psychiatry at the Cantonal Hospital St. Gallen, where she also established a sleep diagnostics department. She’s active in training and supervising medical staff, conducting expert evaluations, and coordinating interdisciplinary care for Long COVID, trauma, and chronic pain. Since 2025, she has also been affiliated with the University Hospital Basel. Her professional journey reflects leadership in clinical development, patient-centered innovations, and academic collaboration.

🏆 Awards & Honors:

Dr. Schmid’s excellence in research and clinical work has been recognized with multiple awards. She received the prestigious Max Planck Society Fellowship (1998–2001) and the Heraeus Foundation Award in 2000. She has won poster prizes at national congresses for work in psychotraumatology (SAPPM/SPS 2022) and sleep-pain therapy (SGPP 2022). She holds the Certificate of Competence in Sleep Medicine, Psycho-Oncology, and is a certified CBT/DBT/IPT/EMDR therapist. She’s a frequent speaker in consultant psychiatry and psychosomatics curricula across Switzerland and Germany, and has led training programs for medical communication, CBT-insomnia, and trauma therapy. Her habilitation (2023) and over 40 peer-reviewed publications reflect sustained academic achievement. Additionally, she has supervised doctoral and master’s theses and collaborated in major clinical research projects, including Long COVID, narcolepsy, and psychosomatic gynecology. These honors and contributions underscore her qualification for the Research for Women Researcher Award.

🔬 Research Focus:

Dr. Schmid’s research bridges psychosomatic medicine, neuroendocrinology, and sleep science, with emphasis on chronic pain, trauma, stress disorders, and Long COVID. Her work explores how hormonal rhythms, sleep patterns, and mental health interact—using sleep EEG, endocrine markers, and clinical interventions. She developed novel group therapies for narcolepsy, dizziness, and insomnia and led outcome evaluations for interdisciplinary multimodal pain therapy (IMPT). Her recent focus includes psychosocial recovery in healthcare workers post-COVID, and pilot studies on plasmapheresis in chronic fatigue syndrome. She also investigates cognitive outcomes, emotion regulation, and therapeutic online models, especially for vulnerable populations. Her research integrates clinical trials, neurobiology, and psychotherapy, contributing to evidence-based advancements in psychosomatic practice. She leads projects at the Cantonal Hospital St. Gallen and collaborates with researchers across neurology, gynecology, and internal medicine, making her research highly interdisciplinary and translational in nature.

📚 Publications Top Notes:

  • 🧠 Increased GH Response to Apomorphine in Parkinson vs MSA (Arch Neurol, 2001)

  • 🍔 Ghrelin Stimulates Appetite, GH, ACTH, Cortisol in Normals (Sleep Res, 2005)

  • 🛌 Nocturnal Ghrelin Levels & Sleep EEG Correlation (Psychoneuroendocrinology, 2006)

  • 🌙 CRH1-Antagonist Improves Sleep EEG in Depression (J Psychiatr Res, 2004)

  • 🌀 Dizziness and Anxiety – A Psychosomatic Link (Health Qual Life Outcomes, 2020)

  • 😴 Ghrelin Promotes Deep Sleep in Humans (AJPEM, 2003)

  • 🧬 CRH Test, Sleep, and Depression Vulnerability (J Psychiatr Res, 2008)

  • 🧪 Cortisol and Sleep Depth in Depression (J Psychiatr Res, 2008)

  • 🦠 HPA Axis & Cytokines in Depression (J Psychiatr Res, 2003)

  • 🧬 Factors Affecting HPA Reactivity in Depression (Neuropsychopharmacology, 2003)

  • 🧘‍♀️ Long COVID & Mental Health in Healthcare Workers (In Prep, 2025)

  • 🛏 IMPT Effectiveness in Chronic Pain-Related Insomnia (In Progress)

  • 🎯 Group Therapy in Narcolepsy: Emotion Regulation & Acceptance (2021-2022)

  • 🎓 CBT-Insomnia Education for Non-Psychiatrists (Ongoing Teaching)

✅ Conclusion:

PD Dr. med. Dagmar A. Schmid is an exceptionally qualified and impactful candidate for the Research for Women Researcher Award. Her integrative, patient-centered research, particularly in sleep medicine, psychotraumatology, and Long COVID, directly contributes to improving women’s health. Combined with her extensive clinical leadership, educational outreach, and publication record, she exemplifies the spirit of this award.

Xiaoyan Wang | Immunology Cellular Interactions | Best Paper Award

Published on by Cell Biologist

Ms. Xiaoyan Wang | Immunology Cellular Interactions | Best Paper Award

Ms. Xiaoyan Wang | Fudan University | China

Dr. Xiaoyan Wang is a dedicated cardiologist and postdoctoral fellow at Fudan University with a strong background in both clinical practice and cardiovascular research. With over a decade of academic training and medical experience, she has built expertise in ventricular remodeling, percutaneous coronary interventions, and immune responses in heart diseases. Under the mentorship of esteemed scholars such as Dr. Yunzeng Zou and Academician Yaling Han, she has published extensively in high-impact journals, reflecting her commitment to scientific advancement. Dr. Wang is currently a scholar in Harvard Medical School’s Global Clinical Scholars Research Training program and also serves as a section editor for the AME Clinical Trials Review. She actively contributes to academic communities, notably by organizing the “Excellent Academic Research Communication Club.” Her work bridges translational medicine and clinical application, aiming to improve cardiovascular patient outcomes through innovative, evidence-based approaches.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Outstanding Academic Credentials: Dr. Wang has earned her PhD from the prestigious Fudan University and is currently in the Harvard Medical School’s Global Clinical Scholars Research Training Program, signaling a top-tier academic and global research profile.

  2. Dual Research Strength in Basic and Clinical Sciences: She demonstrates an exceptional ability to bridge molecular mechanisms (e.g., immune pathways, cGAS-STING, miRNAs, circular RNAs) with clinical relevance (e.g., myocardial infarction prognosis, anemia impact in PCI), making her work highly translational.

  3. High-Impact Publications: First-author or co-first-author in peer-reviewed journals such as Signal Transduction and Targeted Therapy, Angiology, and Frontiers in Cardiovascular Medicine, with publications tackling cutting-edge cardiovascular topics.

  4. Collaborative and Interdisciplinary Focus: Contributions across institutions and disciplines—partnering with bioinformaticians, clinicians, and molecular scientists—demonstrate strong collaboration skills.

  5. Recognition & Editorial Role: Multiple awards (CPSF Fellowship, Super Postdoc at Fudan) and an editorial position at AME Clinical Trials Review show leadership and peer acknowledgment.

🛠️ Areas for Improvement:

  1. More First-Author Lead on Recent Papers: Although she holds strong co-first authorships and collaborative contributions, maintaining or increasing sole first-author outputs on impactful papers would further strengthen individual scholarly identity.

  2. Increased International Conference Visibility: While she has presented at JCS, continued or expanded visibility in global cardiovascular congresses (e.g., AHA, ESC, ACC) would enhance recognition.

  3. Grant Leadership: Future grant applications as a principal investigator (rather than team member) could affirm her leadership in project design and execution.

🎓 Education :

Dr. Xiaoyan Wang holds a Ph.D. from Fudan University’s Zhongshan Hospital (2016–2019), where she conducted fundamental research on ventricular remodeling under Dr. Yunzeng Zou’s mentorship, supported by prestigious national fellowships. She earned her Master’s degree from Dalian Medical University (2013–2016), focusing on clinical research in percutaneous coronary intervention, under Academician Yaling Han. Her academic foundation was laid with a Bachelor’s degree in Medicine from Fujian Medical University (2007–2012). Currently, she is advancing her research and clinical skills in the prestigious Global Clinical Scholars Research Training Program at Harvard Medical School (2024–2025), blending in-person and online modules. Her multi-tiered education reflects a deep integration of basic science, translational medicine, and clinical practice in cardiovascular health, equipping her to lead high-impact research and patient care initiatives.

💼 Experience:

Dr. Wang is currently a Postdoctoral Fellow at Fudan University (since 09/2023), working under Prof. Yunzeng Zou. She is also the organizer of the Excellent Academic Research Communication Club, promoting interdisciplinary dialogue. From 07/2022 to 07/2023, she served as a cardiologist at Shanghai Jiaotong University’s Ruijin Hospital, and from 2019 to 2022, as a resident in internal medicine at Zhongshan Hospital. In 2024, she began contributing as a section editor for AME Clinical Trials Review, enhancing the quality and visibility of clinical trial research. Her experience spans clinical cardiology, postdoctoral research, editorial responsibilities, and academic leadership. These roles have solidified her ability to translate scientific knowledge into medical practice, particularly in the cardiovascular field.

🏆 Awards & Honors:

Dr. Wang has received numerous accolades recognizing her academic excellence and research impact. In 2023, she was awarded both the Postdoctoral Fellowship Program of the China Postdoctoral Science Foundation (CPSF) and the prestigious Super Postdoctoral Fellowship of Fudan University, underscoring her leadership in postdoctoral research. Her communication and writing skills were acknowledged with the Third Prize in the 8th “Buchang Cup” Young Physician Essay Contest (2019). She also presented Late Breaking Cohort Studies at the Japanese Circulation Society (JCS) Annual Meeting 2019, reflecting international recognition of her scientific contributions. These honors reflect her potential as a rising leader in cardiovascular medicine and support her suitability for the Best Paper Award.

🔬 Research Focus :

Dr. Wang’s research focuses on cardiovascular disease mechanisms, particularly immune system regulation, ventricular remodeling, and the molecular basis of heart failure. Her Ph.D. and postdoctoral studies have addressed the cGAS-STING pathway, miRNA biomarkers, circular RNAs, and inflammation-related signaling in cardiovascular dysfunction. She has also explored clinical prognostic models, such as CHA2DS2-VASc scoring, and interventions including left atrial appendage occlusion and shock wave therapy for ischemic cardiomyopathy. Her dual interest in basic science and clinical outcomes allows her to design translational research that bridges laboratory findings and therapeutic advancements. With a strong publication record and ongoing involvement in global research training at Harvard Medical School, her work aims to inform precision medicine strategies in cardiology.

📚 Publication Titles Top Notes:

  1. 🧠 The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications

  2. 🔗 The connection of immune response and cGAS-STING pathway in cardiovascular disease

  3. 🐭 Left ventricular response in hypertrophy-to-failure transition: roles of Akt, β-arrestin-2, and CaMKII

  4. 💉 Circulating miRNAs in hypertension: diagnostic value and bioinformatics analysis

  5. 🧪 Galectin-3 inhibition improves endothelial progenitor function via autophagy suppression

  6. 🔄 Circular RNA in cardiovascular disease

📌 Conclusion:

Dr. Xiaoyan Wang is highly suitable for the Research for Best Paper Award. Her profile reflects a rare and valuable integration of basic cardiovascular science and clinical innovation, with high-impact, well-cited publications and ongoing international training. Her trajectory, marked by excellence, discipline, and collaborative leadership, meets and exceeds the criteria for this award.

Yidong Wei | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Prof. Yidong Wei | Immunology Cellular Interactions | Best Researcher Award

Prof. Yidong Wei , Shanghai Tenth People’s Hospital, Tongji University , China

Dr. Yidong Wei, M.D., Ph.D., FACC, is a distinguished professor and the Chief of Cardiology at Shanghai Tenth People’s Hospital, Tongji University. He also holds a clinician management role at the Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford. With a strong foundation in both clinical and translational research, Dr. Wei has built an internationally recognized career focused on interventional cardiology, cardiac electrophysiology, and cardiovascular epidemiology. He is a Fellow of the American College of Cardiology, reflecting his global academic influence. Known for bridging clinical care with bench-side discovery, his work has advanced understanding in myocardial infarction, heart failure, and calcium signaling in cardiomyocytes. With numerous high-impact publications and leadership in multicenter registries like NOAFCAMI-SH, Dr. Wei’s contributions are widely cited and clinically relevant. His dual academic and clinical roles across China and the UK highlight his dedication to innovation, international collaboration, and excellence in cardiovascular medicine.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. High-Impact Research Output:
    Dr. Wei has authored or co-authored more than 18 recent peer-reviewed publications in prestigious journals such as Diabetes Metabolism Research and Reviews, Redox Biology, Cardiovascular Diabetology, and ESC Heart Failure. Many of these works are already cited, indicating early academic impact and relevance.

  2. Dual Focus – Basic and Clinical Science:
    His research bridges the gap between molecular mechanisms (e.g., calcium signaling, TRIM21, PTEN) and clinical cardiology (e.g., atrial fibrillation, myocardial infarction, cardiac remodeling), highlighting a robust translational focus.

  3. Leadership and Collaboration:
    He serves as Chief of Cardiology at Shanghai Tenth People’s Hospital and a Clinician Manager at the University of Oxford, demonstrating international leadership and cross-border collaboration.

  4. Registry Leadership (NOAFCAMI-SH):
    His work through the NOAFCAMI-SH registry provides real-world evidence on cardiovascular disease progression, risk prediction, and treatment response—critical for patient-centered care.

  5. Prestigious Recognition:
    Dr. Wei is a Fellow of the American College of Cardiology (FACC), a title reserved for top-tier cardiovascular professionals with sustained excellence.

⚠️ Areas for Improvement:

  1. Broader International Research Leadership:
    While Dr. Wei has strong China–UK collaborations, leading global multicenter clinical trials or international consortia would further solidify his standing.

  2. Public Engagement and Knowledge Translation:
    Though academically prolific, increased involvement in public health education or policy advocacy could amplify the real-world impact of his research.

  3. Mentorship Track Record Visibility:
    Highlighting mentorship of junior researchers and postdocs more explicitly in profiles and bios would enhance his case for a holistic academic leadership award.

🎓 Education:

Dr. Wei began his medical education at Henan Medical University, where he completed clinical training with a focus on cardiovascular medicine. Driven by a passion for research, he pursued and completed his Ph.D. in 2004, with a specialization in cardiac electrophysiology and calcium signaling pathways. His graduate studies were complemented by advanced basic science training at the University of Kentucky, USA, a leading institution in biomedical research. Between 2004 and 2006, Dr. Wei completed postdoctoral research, focusing on the molecular mechanisms of cardiac dysfunction and electrophysiology. His educational background reflects a balanced integration of rigorous clinical education and innovative research development, equipping him with the tools necessary to bridge bedside care with laboratory insights. This foundation has allowed Dr. Wei to contribute to both academic medicine and cutting-edge cardiovascular research, distinguishing him as a leader with comprehensive and global training in the field.

🏥 Experience:

With over two decades of experience, Dr. Yidong Wei serves as Professor and Chief of the Department of Cardiology at Shanghai Tenth People’s Hospital, Tongji University. His role extends internationally, acting as Clinician Manager at the University of Oxford’s Centre for Diabetes, Endocrinology and Metabolism. His clinical expertise spans interventional cardiology, acute coronary syndromes, and electrophysiological interventions, while his research roles emphasize trial design, biomarker discovery, and cellular cardiology. He has led and contributed to large-scale registries like NOAFCAMI-SH, generating evidence that informs guidelines for myocardial infarction and atrial fibrillation. His professional experience combines healthcare leadership, cross-border academic collaboration, and impactful research. As a Fellow of the American College of Cardiology, he is actively engaged in academic societies and peer-reviewed journals. Dr. Wei’s experience reflects an enduring commitment to patient care, innovation in research, and mentorship of future cardiology leaders, marking him as a high-impact contributor in his field.

🔬 Research Focus:

Dr. Yidong Wei’s research lies at the intersection of clinical cardiology and molecular medicine. He focuses on interventional cardiology, atrial fibrillation, myocardial infarction, and calcium signaling pathways in cardiac myocytes. A major theme in his work is the electrophysiological basis of heart failure and age-related changes in ventricular function. Using techniques like patch clamping, calcium imaging, laser confocal microscopy, and molecular biology, he investigates calcium channel regulation and excitation-contraction coupling in cardiac cells. Clinically, he leads research through the NOAFCAMI-SH registry, analyzing systemic inflammation, hyperglycemia, atrial fibrillation, and long-term cardiac outcomes. His work advances the understanding of post-infarction remodeling and atrial pathology. Combining basic science with real-world data, Dr. Wei’s research bridges gaps in translational cardiology and offers therapeutic targets for chronic cardiac conditions. His integrative approach makes him a pioneer in translating bench findings into bedside impact, with potential to redefine cardiac care strategies globally.

📚 Publications Top Notes:

  1. 📈 Association of stress hyperglycemia ratio with atrial fibrillation and outcomes in myocardial infarction

  2. 🧪 Prognostic implications of systemic immune-inflammation index in MI patients with and without diabetes

  3. 🧬 TRIM21 deficiency protects heart post-MI by reducing oxidative stress

  4. 🫀 4S-AF scheme for characterizing atrial fibrillation after myocardial infarction

  5. 🔬 TRIM21 worsens cardiac injury via M1 macrophage polarization post-MI

  6. 🧮 Stress hyperglycemia and outcomes in MI with and without diabetes mellitus

  7. 💉 ZPI protects endothelium via PI3K/Akt pathway activation against ox-LDL

  8. 📊 Atrial fibrillation’s prognosis across heart failure subtypes post-MI

  9. 🕒 Five-year outcomes post left atrial appendage occlusion

  10. 🧫 PTEN and serum deprivation-induced cytotoxicity via PI3K/AKT pathway

🧾 Conclusion:

Dr. Yidong Wei stands out as a highly suitable candidate for the Best Researcher Award. His contributions to cardiovascular research—spanning cutting-edge basic science to influential clinical trials—are both innovative and impactful. His leadership roles, international presence, and translational focus align perfectly with the goals of this prestigious recognition. Given his trajectory, Dr. Wei is not only a leader in current cardiovascular research but also a driver of future scientific breakthroughs.